Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
AHJ S1E4: TAVI 10 Year Anniversary
2018 marks the 10 year anniversary of the TAVI device, short for the Transcatheter Aortic Valve Implantation. The TAVI system enables the replacement of a diseased aortic valve without open-heart surgery or surgical removal of the native valve.
This minimally invasive surgical option reduces operating time and allows for a shortened recovery period for patients.
AHJ met with the cardiologist teams in Melbourne’s Epworth and Alfred Hospital who have involved in implanting the device over the past 10 years.
Interviews:
- Associate Professor Tony Walton, Epworth Hospital, Director of Catheter Laboratory and Deputy Director of Cardiology – Alfred Health
- Associate Professor Ron Dick, Director of Cardiac Sciences – Epworth Healthcare
- Professor Stephen Duffy, Alfred Health
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
Landmark brain shape study
For over a century, researchers have thought that the patterns of brain activity that define our experiences, hopes and dreams are determined by how different brain regions communicate with each other through a complex web of trillions of cellular connections.
Now, a Monash University Turner Institute for Brain and Mental Health-led study has examined more than 10,000 different maps of human brain activity and found that the overall shape of a person’s brain exerts a far greater influence on how we think, feel and behave than its intricate neuronal connectivity.